Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HanX Biopharma Signs $51.5 Million Agreement for Onconova MDS Treatment

publication date: May 13, 2019

HanX Biopharma, a China oncology company, in-licensed China rights to a Phase III candidate for myelodysplastic syndromes from Onconova in a $51.5 million agreement. HanX agreed to pay $4 million upfront ($2 million fee and $2 million investment) plus put $2 million in escrow for China clinical development of rigosertib in patients with MDS. It will also pay Onconova up to $45.5 million in regulatory and sales milestones. In addition, HanX expects to test rigosertib together with its PD-1 antibody, now in China Phase II/III clinical trials. More details....

Stock Symbol: (NSDQ: ONTX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.